Delving into the Latest Updates on Metastatix, Inc. with Synapse

Overview

Primary Objectives:
To determine the maximum tolerated dose (MTD) and the recommended Phase II dose(s) and schedule of MSX-122
To characterize the dose limiting toxicities (DLTs) and determine the overall safety and tolerability of MSX-122
Secondary Objectives:
To determine the pharmacokinetics and pharmacodynamics of orally administered MSX-122
To evaluate the preliminary evidence for anti-tumor activity of MSX-122
To perform correlative studies to elucidate signaling pathways involved in CXCR4 activation in blood and optional tissue specimens by IHC (immunohistochemistry) and RPPA (reverse phase protein microarrays)

Start Date01 Nov 2007

Sponsor / Collaborator

Metastatix, Inc.

100 Clinical Results associated with Metastatix, Inc.

Login to view more data

0 Patents (Medical) associated with Metastatix, Inc.

Login to view more data

100 Deals associated with Metastatix, Inc.

Login to view more data

100 Translational Medicine associated with Metastatix, Inc.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 28 Apr 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Other

1

Login to view more data